鲍曼不动杆菌的临床分布与耐药性监测

目的 了解临床分离的鲍曼不动杆菌临床分布和耐药情况,为有效治疗和临床控制感染提供依据.方法 收集2009年1月-2010年12月临床分离的339株鲍曼不动杆菌,记录标本来源、感染科室分布,并采用纸片扩散性进行药敏试验,按CLSI 2009年版标准判读药敏试验结果,采用WHONET5.3软件进行数据分析.结果 标本来源以呼吸道为主,占74.9％;科室分布以重症监护病房(ICU)最多,占28.9％.与2009年监测结果相比,鲍曼不动杆菌对头孢哌酮/舒巴坦的耐药率从25.3％下降至2010年的18.3％,对米诺环素的耐药率从20.3％上升至2010年的37.7％,对亚胺培南和美罗培南的耐药率分别从57.5％、62.7％上升至2010年的66.5％、70.7％,对其他抗菌药物的耐药率均＞50.3％.结论 鲍曼不动杆菌耐药性仍呈增长趋势,对头孢哌酮/舒巴坦、米诺环素仍有良好的抗菌活性.

Clinical distribution and drug resistance of Acinetobacter baumannii

Objective To investigate the clinical distribution and drug resistance of Acinetobacter baumannii and offer assistance for treatment of nosocomial infection.Methods Totally 339 Acinetobacter baumannii strains were isolated from January 2009 to December 2010.Susceptibility of Acinetobacter baumannii to antimicrobials were tested by using Kirby-Bauer method.The data were analyzed with WHONET5.3 software according to CLSI2009 standard.Results The samples were mainly collected from respiratory tract（74.9%）,the noisocomial infection of Acinelobacter baumannii was higher in ICU（28.9%）.The resistance rate of Acinetobacter baumanoii to cefoperazone/sulbactem was reduced from 25.3% in 2009 to 18.3% in 2010,the resistance rate to minocycline was increased from 20.3% in 2009 to 37.7% in 2010,while to imipenem and meropenem were increased from 57.5% and 62.7% in 2009 to 66.5% and 70.7% in 2010.The resistance rate to other antimicrobials were all over 50.3%.Conclusion The resistance of Acinelobacter baumannii to antimicrobials shows a asecending trend,but is still susceptible to cefoperazone/sulbactem and minocycline.